EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN..

9th Joint ECTRIMS-ACTRIMS meeting

 

11–13 October 2023 Milan
Close
N. Poster
Poster title
Applicant name
Status
  1-P Inclusion of optic neuritis improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis Lilyana Amezcua Received Received
  2-P How Well Do Junior Neurology Residents Recognize Multiple Sclerosis? Analysis of the Close the Loop Resident Clinical Acumen Project Claudia Zbrzeski Received Received
  3-P Clinical and radiological phenotype of adult-onset neurogenetic diseases mimicking multiple sclerosis: a multinational observational study Gabrielle Macaron Received Received
  18-P Humoral signatures of MOG-antibody associated disease Jan Lünemann Received Received
  21-P Clinical predictors of outcomes in pediatric myelin oligodendrocyte glycoprotein antibody disease Alexandra Kornbluh Received Received
  42-P Patterns and Predictors of Conversion from Relapsing-Remitting to Secondary Progressive MS: A Longitudinal Study Using the Danish Multiple Sclerosis Registry Melinda Magyari Received Received
  45-P Disease modifying therapy use among people living with multiple sclerosis based on socioeconomic status and urban/rural residence: a retrospective cohort study from Alberta, Canada Erin Balcom Received Received
  47-P Epidemiology of Relapsing Remitting Multiple Sclerosis in Chile between 2010 and 2021 Lorna Galleguillos Received Received
  54-P Prognostic factors of Disease Activity in Newly-diagnosed Teriflunomide Treated Patients with Multiple Sclerosis - A Nationwide Danish Study Mie Reith Mahler Received Received
  62-P Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies: a monocentric retrospective study Oussama Sahloul Received Received
  71-P Performance of gold-standard cognitive measures for detecting change over time: Longitudinal analysis of retrospective data Victoria Leavitt Received Received
  87-P Patient-reported factors impacting well-being in individuals with multiple sclerosis - a cross-sectional study Sabrina Islamoska Received Received
  94-P Elevated Incidence and Prevalence of Peripartum Mental Illness in Women with Multiple Sclerosis Ruth Ann Marrie Received Received
  140-P Age-associated change in Th17 and cytokine response in Multiple Sclerosis Zongqi Xia Received Received
  150-P Cytomegalovirus in multiple sclerosis patients: how does it interact with the infection by Epstein-Barr virus and human herpesvirus 6A/B? Roberto Alvarez-Lafuente Received Received
  151-P Environmental risk factors in multiple sclerosis. FRAMES study. Roberto Álvarez-Lafuente Received Received
  162-P Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies Victoria Findlen Received Received
  192-P Contribution of 7T brain MRI to the detection of cortical lesions at the earliest stage of multiple sclerosis. Jean Pelletier Received Received
  203-P Depicting longitudinal MS disease course using lesion parenchymal fraction (LPF): a quantified expression of the topographical model of MS Stephen Krieger Received Received
  219-P Creation and performance of the International MOGAD Diagnostic Criteria Brenda Banwell Received Received
  237-P Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis Synne Brune-Ingebretsen Received Received
  239-P Serum neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients Antonio Bertolotto Received Received
  276-P Phase III MIRANTIBUS trial: results of 48 weeks treatment with divozilimab versus teriflunomide in relapsing multiple sclerosis. Alexey Boyko Received Received
  282-P Phase I trial of faecal microbiota transplantation in MS Bob van Oosten Received Received
  295-P VISIONARY-MS Topline Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis Heidi Beadnall Received Received
  296-P harnessing the endogenous adaptive response to hypoxia-ischemia as a therapy for neurodegeneration in multiple sclerosis Carlos Camara Received Received
  309-P DISCOntinuation of disease-modifying therapies in Multiple Sclerosis (DISCOMS): Primary results of the extension trial John Corboy Received Received
  314-P Endogenous IgG4 Concentration Impacts Natalizumab Arm Exchange and Intact Drug Pharmacokinetics Bradley Messmer Received Received
  323-P The role of ganglion cell inner plexiform layer thickness in evaluating the neuroprotective role of phenytoin in the visual pathway Srikirti Kodali Received Received
  325-P Risk of cardiovascular disease in patients treated with fingolimod compared to natalizumab: A nationwide cohort study in Denmark Elisabeth Framke Received Received
  331-P Stopping Fingolimod is associated with a high risk of radiological disease reactivation Rolf Holm Received Received
  345-P Disparities in DMT Treatment Access: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies Victoria Leavitt Received Received
  359-P Efficacy and safety of diroximel fumarate compared with interferon beta-1a in relapsing-remitting multiple sclerosis: Propensity Score Matching Analysis of Phase 3 Data from EVOLVE-MS-1 and DECIDE Christin Henning Received Received
  360-P Incidence of new menstrual cycle disorders in a cohort of 120 women with multiple sclerosis treated with cladribine: a single-arm oberservational multi-center cohort study Birte Elias-Hamp Received Received
  383-P Is Fatigue in MS the same one manifesting as Wearing-off Symptom in Natalizumab treated patients? Giuseppe Magro Received Received
  395-P Trait Conscientiousness and Multiple Sclerosis: Predicting Disease Progression and Assessing the Effects of an App-Supported Behavioral Intervention Michael Jaworski Received Received
  417-P Comparison of Vision-Related Quality of Life in AQP4 NMOSD and MOGAD Adnan A. Gassan Received Received
  418-P Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease and MOG/AQP4 Testing Landscape in Canada Jodie Burton Received Received
  423-P Assessing the performance of cell based assays for MOGAD in the real world setting of a resource poor region - Impact of the international MOGAD diagnostic criteria Lekha Pandit Received Received
  424-P Depression and Cognition in Multiple Sclerosis: Longitudinal Evidence of a Specific Link to Executive Control Jordyn Anderson Received Received
  450-P The multiple sclerosis prodrome: Rates of physician visits were elevated in the 15 years before a first demyelinating event and differed by age and sex; an international matched cohort study. Helen Tremlett Received Received
  451-P Chronic infections and malignancy screening in Mexican patients with multiple sclerosis before initiating disease modifying treatments. lizeth zertuche Received Received
  453-P Clinical outcomes and treatment strategy of multiple sclerosis in China: Results from a real-world cross-sectional survey Wenhao Wang Received Received
  463-P Pregnancy reduces the risk of reaching irreversible EDSS 3 in women with multiple sclerosis, but theres a catch! Vilija Jokubaitis Received Received
  464-P RESPONSE, a French cohort of pregnant women with MS and related disorders and their children until the age of 6. Protocol and baseline characteristics. Sandra Vukusic Received Received
  485-P MS Falls InsightTrack (MS-FIT): Design and Stakeholder Perspectives on a Closed-loop Falls Monitoring and Prevention Application for MS Clinical Practice Valerie Block Received Received
  490-P The socio-economic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study Viktoria Papp Received Received
  494-P Comorbidity in the aging population with multiple sclerosis -- A nationwide cross-sectional study Rolf Holm Received Received
  510-P Pathogenic cerebrospinal fluid antibodies in oligoclonal band-negative primary progressive MS patients Jamie Wong Received Received
  519-P A single cell multi-omics map of cell type specific mechanistic drivers of multiple sclerosis lesions Maria Louise Elkjr Received Received
  527-P SARS-CoV-2 mRNA vaccination affects antibody and cellular immune responses after B-cell depletion therapies Erin Longbrake Received Received
  530-P Cervical lymph nodes in patients with multiple sclerosis show an overrepresentation of memory B cells and a disturbed germinal center reaction Sini Laakso Received Received
  538-P Expanded T lymphocyte clones in the cerebrospinal fluid of multiple sclerosis patients are specific for autologous Epstein-Barr virus infected B lymphocytes. John Lindsey Received Received
  548-P In vitro infection of CNS-derived cells with Epstein-Barr virus using a B-cell transfer method Roberto Alfonso Received Received
  551-P Inverse association between mediterranean diet and risk of multiple sclerosis Lars Alfredsson Received Received
  574-P Choroid plexus volume and slowly expanding lesions as inflammatory markers in relapsing multiple sclerosis. Muhammad Raghib Received Received
  575-P Choroid plexus volume correlates with advanced MRI metrics in relapsing multiple sclerosis. Muhammad Raghib Received Received
  599-P The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with acute optic neuritis. Gorm Pihl-Jensen Received Received
  615-P Neurodegeneration may occur without evidence of clinical or neuroinflammatory relapse in recently-diagnosed relapsing-remitting multiple sclerosis Rozanna Meijboom Received Received
  634-P Plasma IgG Aggregates as Biomarkers for MS and for Diagnosing SPMS Xiaoli Yu Received Received
  638-P Trends, Features, and Utility of Testing Myelin Oligodendrocyte Glycoprotein Autoantibodies in CSF Jodie Burton Received Received
  663-P Stool glial fibrillary acidic protein is a biomarker of progressive multiple sclerosis and predicts disease worsening Luke Schwerdtfeger Received Received
  672-P Improving Precision Medicine for Multiple Sclerosis with Uncertainty-Aware Causal Models Jean-Pierre Falet Received Received
  700-P Inhibiting CEMIP Activity in Demyelinating Lesions Promotes Functional Remyelination Larry Sherman Received Received
  703-P The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in murine models of multiple sclerosis Torbjrn Krkenes Received Received
  708-P Reduction in Absolute Lymphocyte Count in Patients Transitioning from Dimethyl Fumarate to Diroximel Fumarate. Kyle Smoot Received Received
  717-P Prediction of gammaglobulin decrease during rituximab treatment in MS Sandra Kallin Received Received
  735-P New methods to estimate the effect of disease modifying treatment on disability in multiple sclerosis in open observational cohort studies. Melinda Magyari Received Received
  736-P Descriptive demographic and clinical characteristics for Alemtuzumab treated patients with MS vs. other disease modifying therapies treated patients with MS: Preliminary results of a feasibility analysis Jian-Yu E Received Received
  742-P A Retrospective Analysis of Natalizumab First-line Versus Later-line Use in Multiple Sclerosis Treatment: Evidence from a US Claims Database Study Mattia Gianinazzi Received Received
  760-P Grey Matter Structural Changes and their Correlation with Tremor Severity in Multiple Sclerosis: A Case-Control Study Ahmed Bayoumi Received Received
  761-P When does multiple sclerosis (MS) start? Findings from an international pediatric-onset MS population suggests higher than expected health care use from birth Helen Tremlett Received Received
  766-P Increased Aerobic Glycolysis in Normal Appearing White Matter of Multiple Sclerosis Patients Matthew Brier Received Received
  768-P Analysis of the Global Landscape of Multiple Sclerosis Research Bruce Bebo Received Received
  780-P The Role of Surveillance MRI in Paediatric-onset MOGAD and NMOSD: A Retrospective Cohort Study Paridhi Shah Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
07:45
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

9th Joint ECTRIMS-ACTRIMS meeting

 

11–13 October 2023 Milan
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 11/10/2023 TO 11/10/2023
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert